Relatlimab
Recurrent Ureter Urothelial Carcinoma
M.D. Anderson Cancer Centermonoclonal_antibodyPhase 2Active
CCC
53/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 38/ 100
- Competitive Position
- 95/ 100
Competitive context
3 Active assets in the Recurrent Ureter Urothelial Carcinoma cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
PAN-FGFR TYROSINE KINASE INHIBITOR JNJ-42756493 National Cancer Institute (NCI) | Phase 2 | B |
Atezolizumab National Cancer Institute (NCI) | Phase 2 | B |
ERIBULIN MONOMETHANESULFONATE National Cancer Institute (NCI) | Phase 2 | CCC |
Same molecule, other indications
Relatlimab is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →